EditorialThe heart in anaphylaxis
References (33)
- et al.
Experimental cardiac anaphylaxis: physiologic, pharmacologic, and biochemical aspects of immune reactions in the isolated heart
Am J Cardiol
(1969) - et al.
The biologic consequences of the immediate-type hypersensitivity transferred from man to monkey
J ALLERY
(1966) - et al.
IgE-mediated hypersensitivity in human heart tissue: histamine release and functional changes
J ALLERGY CLIN IMMUNOL
(1986) - et al.
Cardiac disease accompanying allergic drug reactions
J ALLERGY
(1970) - et al.
Electrocardiographic changes associated with penicillin anaphylaxis
Chest
(1973) - et al.
Reversible acute cardiac injury during cefoxitin-induced anaphylaxis in a patient with normal coronary arteries
Am J Med
(1984) - et al.
Physiology of immediate reaction of anaphylaxis in guinea pig
J Exp Med
(1910) - et al.
Respiratory and circulatory alterations induced by acetylglyceryl ether phosphorylcholine (AGEPC): a mediator of IgE anaphylaxis in the rabbit
Am Rev Respir Dis
(1980) - et al.
Separation of primary and secondary cardiovascular events in systemic anaphylaxis
Circ Res
(1977) - et al.
Roles of histamine in cardiac dysfunction
Release of chemical mediators from partially purified human lung mast cells
J Immunol
Periarterial mast cells in coronary atheroma and thrombosis
J Path Bacteriol
Effects of histamine on the cardiovascular and respiratory system: dysrrhythmias caused by histamine release in guinea pig and human hearts
Klin Wochenschr
Leukotriene C4 is released from the anaphylactic heart: a case for its direct negative isotropic effect
Acetylglyceryl ether phosphorylcholine (AGEPC): a putative mediator of cardiac anaphylaxis in the guinea pig
Circ Res
The heart as a target organ in systemic allergic reactions: comparison of cardiac anaphylaxis in vivo and in vitro
Circ Res
Cited by (46)
Atrial Fibrillation in Anaphylaxis
2017, American Journal of MedicineCitation Excerpt :In these cases, the very interesting point of discussion was: which should be first, the treatment of the anaphylaxis or of the cardiac event? Treatment with H1 antagonists is controversial; in fact, these drugs prevent slow atrioventricular conduction and inhibit ventricular fibrillation,4 but they are considered safe. Corticosteroids are potent anti-inflammatory and immunosuppressant agents.
The Use of Vasopressors and Inotropes in the Emergency Medical Treatment of Shock
2008, Emergency Medicine Clinics of North AmericaCitation Excerpt :Shock occurs in 30% to 50% percent of cases [132,133]. Shock in anaphylaxis shares variable components with hypovolemic shock caused by capillary fluid leak, distributive shock caused by the loss of vasomotor tone, and cardiogenic shock caused by inotropic reductions [131–134]. Knowledge of this physiologic distribution is important to the emergency management of anaphylaxis and specifically to the selection of therapies.
Anaphylactic shock: The advantages of intra aortic balloon counter pulsation for the treatment of heart failure
2007, ResuscitationCitation Excerpt :The low arterial pressure and consequent myocardial ischaemia combined with the vasoconstrictive action of the epinephrine could explain the appearance of the abnormal T waves and ST segment.5 Even in subjects without coronary disease the administration of adrenaline results in abnormal signs in the ST segment, suggestive of heart failure.6 In anaphylactic shock the systematic vasoplegia may induce severe arterial hypotension.
Anaphylaxis: A review of causes and mechanisms
2002, Journal of Allergy and Clinical ImmunologyAtrial fibrillation associated with anaphylaxis during venom and pollen immunotherapy
2002, Annals of Allergy, Asthma and Immunology